Cohance Lifesciences is a global CDMO platform helping pharmaceutical innovators solve complex development and manufacturing challenges across Small Molecules, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry. Backed by more than 35 years of scientific expertise, an integrated network of manufacturing and R&D facilities across India and the United States, and trusted partnerships with the leading pharmaceutical innovators, Cohance supports customers from process development and scale-up through commercial manufacturing.

In this CDMO overview video, discover how Cohance combines advanced small molecule chemistry expertise, ADC leadership through NJ Bio, specialized nucleic acid chemistry capabilities through Sapala Organics, and robust manufacturing infrastructure to help accelerate the development of next-generation therapies.

Key Highlights:

• Global CDMO platform with expertise across Small Molecules, ADCs, and Nucleic Acid Chemistry
• 35+ years of scientific and manufacturing excellence
• Integrated development, scale-up, and commercial manufacturing capabilities
• Advanced chemistry expertise including HPAPIs, flow chemistry, and complex conjugate chemistry
• ADC capabilities spanning Discovery and IND-enabling chemistry, payload-linkers and bioconjugation
• Specialized nucleic acid chemistry capabilities including amidites, modified nucleosides, GalNAc conjugates, and oligonucleotide building blocks
• Strategic operations across India and the United States

Collaborate. Enhance. Deliver.

Learn more at www.cohance.com

Click here to meet with Cohance at CPHI Milan